RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mayne Pharma Group Stock

Mayne Pharma Group Stocks 2024

Mayne Pharma Group Stocks

79.62 M

Ticker

MYX.AX

ISIN

AU000000MYX0

WKN

A1C821

In 2024, Mayne Pharma Group had 79.62 M outstanding stocks, a -3.11% change from the 82.18 M stocks in the previous year.

The Mayne Pharma Group Stocks history

YEARNUMBER OF STOCKS (undefined AUD)
2027e79.62
2026e79.62
2025e79.62
202479.62
202382.18
202282.3
202178.58
202076.47
201973.75
201873.14
201773.02
2016858
2015715.45
2014645.6
2013443.3
2012214.6
2011215.1
2010178.7
2009106.8
2008106.8
200762
200629.4

Mayne Pharma Group shares outstanding

The number of shares was Mayne Pharma Group in 2023 — This indicates how many shares 82.177 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Mayne Pharma Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Mayne Pharma Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Mayne Pharma Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mayne Pharma Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Mayne Pharma Group Aktienanalyse

What does Mayne Pharma Group do?

Mayne Pharma Group Ltd. is a leading company in the field of pharmaceutical development and production with manufacturing facilities in Australia and the USA. The company is headquartered in Sydney, Australia and employs over 1,100 employees worldwide. The history of Mayne Pharma dates back to 1845 when the company was founded as a manufacturer of herbal medicine. Over the years, the company has evolved and focused on the pharmaceutical industry, eventually being renamed Mayne Nickless Ltd in 1981. In 2000, the company established its subsidiary Mayne Pharma, specializing in the development and production of generic drugs. Through the acquisition of other companies, Mayne Pharma has expanded its product range and expanded into the USA in 2007. Mayne Pharma focuses on the production of generics and specialty pharmaceuticals, which are marketed worldwide through a variety of distribution channels. The company invests heavily in research and development to develop new products and improve existing ones. The goal is to continuously expand the offering and increase market presence. Through the expansion of the product portfolio and the exploration of new markets, Mayne Pharma has gained a strong position in the pharmaceutical industry in recent years. Mayne Pharma is divided into three divisions: generics, specialty pharmaceuticals, and beauty products. The generics division includes a wide range of prescription generic drugs marketed in the USA, Australia, Canada, and other countries. The company is able to produce cost-effective medications to provide affordable drugs to patients worldwide. The specialty pharmaceuticals division focuses on medications for the treatment of diseases such as cancer, pain, and cardiovascular diseases. Mayne Pharma aims to improve treatment outcomes for patients in these areas and has a promising product development pipeline that includes many innovative therapy options. The beauty products division offers a wide range of high-quality skincare products sold worldwide. This includes skin creams, lip care products, and sunscreens. This division is growing steadily and offers great potential, as it operates not only in the healthcare sector but also in the beauty market. Mayne Pharma has a wide range of products, ranging from medications for everyday ailments to life-saving specialty preparations. Key products include: - Doryx: An oral antibiotic therapy for the treatment of mild to moderate acne. - Lonsurf: A cancer-fighting medication that extends the survival time of advanced colorectal cancer patients. - Kapanol: A long-acting opioid for pain relief in patients with severe pain. - Tolsura: An easy-to-use medication for the treatment of fungal infections, particularly suitable for patients who have difficulty swallowing tablets. - Zenavod: A topical medication for the treatment of vaginal infections. - Golden Glow Sunscreen: A high-quality sunscreen with SPF 50+ that prevents skin irritation and sunburn. In conclusion, Mayne Pharma is a proven and innovative company that focuses on the development and production of generics and specialty pharmaceuticals. With its extensive product range and business activities in key international markets, Mayne Pharma has an outstanding reputation in the pharmaceutical industry. Mayne Pharma Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Mayne Pharma Group's Shares Outstanding

Mayne Pharma Group's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Mayne Pharma Group’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Mayne Pharma Group’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Mayne Pharma Group’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Mayne Pharma Group stock

How many stocks are there of Mayne Pharma Group?

The current number of stocks of Mayne Pharma Group is 79.62 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Mayne Pharma Group are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Mayne Pharma Group evolved in recent years?

The number of shares of Mayne Pharma Group has increased by -3.11% gesunken compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Mayne Pharma Group as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Mayne Pharma Group?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Mayne Pharma Group pay?

Over the past 12 months, Mayne Pharma Group paid a dividend of 0.78 AUD . This corresponds to a dividend yield of about 15.15 %. For the coming 12 months, Mayne Pharma Group is expected to pay a dividend of -0.27 AUD.

What is the dividend yield of Mayne Pharma Group?

The current dividend yield of Mayne Pharma Group is 15.15 %.

When does Mayne Pharma Group pay dividends?

Mayne Pharma Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mayne Pharma Group?

Mayne Pharma Group paid dividends every year for the past 1 years.

What is the dividend of Mayne Pharma Group?

For the upcoming 12 months, dividends amounting to -0.27 AUD are expected. This corresponds to a dividend yield of -5.29 %.

In which sector is Mayne Pharma Group located?

Mayne Pharma Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mayne Pharma Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mayne Pharma Group from 1/27/2023 amounting to 0.777 AUD, you needed to have the stock in your portfolio before the ex-date on 1/18/2023.

When did Mayne Pharma Group pay the last dividend?

The last dividend was paid out on 1/27/2023.

What was the dividend of Mayne Pharma Group in the year 2023?

In the year 2023, Mayne Pharma Group distributed 0 AUD as dividends.

In which currency does Mayne Pharma Group pay out the dividend?

The dividends of Mayne Pharma Group are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mayne Pharma Group

Our stock analysis for Mayne Pharma Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mayne Pharma Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.